Grifols Dividend

Dividend criteria checks 0/6

Grifols does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	1.8%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	€0.087
Dividend yield forecast in 3Y	5.8%

Recent dividend updates

No updates

Recent updates

Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?

Apr 20

Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 04

Revenues Working Against Grifols, S.A.'s (BME:GRF) Share Price Following 27% Dive

Mar 01

Is Grifols, S.A. (BME:GRF) Expensive For A Reason? A Look At Its Intrinsic Value

Oct 20

Is Grifols (BME:GRF) A Risky Investment?

Aug 03

Calculating The Fair Value Of Grifols, S.A. (BME:GRF)

May 18

Is Grifols (BME:GRF) Using Too Much Debt?

Apr 30

Grifols (BME:GRF) Seems To Be Using A Lot Of Debt

Nov 18

An Intrinsic Calculation For Grifols, S.A. (BME:GRF) Suggests It's 45% Undervalued

Oct 26

Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load

Aug 18

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if GRF's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GRF's dividend payments have been increasing.

Dividend Yield vs Market

Grifols Dividend Yield vs Market

How does GRF dividend yield compare to the market?
Segment	Dividend Yield
Company (GRF)	n/a
Market Bottom 25% (ES)	2.3%
Market Top 25% (ES)	5.8%
Industry Average (Biotechs)	1.8%
Analyst forecast in 3 Years (GRF)	5.8%

Notable Dividend: Unable to evaluate GRF's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GRF's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate GRF's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as GRF has not reported any payouts.

Grifols Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Price target decreased by 7.1% to €17.40

Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 23%

Consensus EPS estimates fall by 13%

Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings: Revenues in line with analyst expectations

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Revenues Working Against Grifols, S.A.'s (BME:GRF) Share Price Following 27% Dive

Does Grifols (BME:GRF) Have A Healthy Balance Sheet?

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 12%

Benign Growth For Grifols, S.A. (BME:GRF) Underpins Its Share Price

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

New major risk - Share price stability

Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load

Consensus EPS estimates fall by 16%

Third quarter 2023 earnings released

Consensus EPS estimates increase by 45%

Is Grifols, S.A. (BME:GRF) Expensive For A Reason? A Look At Its Intrinsic Value

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Consensus EPS estimates increase by 46%

Consensus EPS estimates fall by 28%

Is Grifols (BME:GRF) A Risky Investment?

New major risk - Financial position

Second quarter 2023 earnings released

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Consensus EPS estimates fall by 12%

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

New major risk - Financial position

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Calculating The Fair Value Of Grifols, S.A. (BME:GRF)

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Launches Alphaid™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic Copd

Consensus EPS estimates fall by 54%

Investor sentiment improves as stock rises 19%

Is Grifols (BME:GRF) Using Too Much Debt?

Consensus EPS estimates increase by 31%

Investor sentiment deteriorates as stock falls 16%

Full year 2022 earnings: Revenues exceed analyst expectations

Consensus EPS estimates fall by 12%

Now 21% undervalued

Grifols, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023

Now 20% undervalued

Grifols (BME:GRF) Seems To Be Using A Lot Of Debt

Insufficient new directors

Price target decreased to €18.53

Grifols, S.A. to Report Q3, 2022 Results on Nov 08, 2022

Grifols Receives FDA Clearance for AlphaID(TM) At Home, the First Free Service for U.S. Consumers to Determine Their Risk for Alpha-1

An Intrinsic Calculation For Grifols, S.A. (BME:GRF) Suggests It's 45% Undervalued

Insufficient new directors

Grifols Announces Management Changes

Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load

Second quarter 2022 earnings: Revenues exceed analyst expectations

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Now 21% undervalued after recent price drop

Now 21% undervalued

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies